Literature DB >> 3933824

Multiple forms of plasminogen activator in human breast tumors.

P O'Grady, H R Lijnen, M J Duffy.   

Abstract

Total plasminogen activator (PA) activity, tissue-type PA (t-PA) activity, urokinase-like PA activity, and immunoreactive t-PA were measured in benign breast tumors (fibroadenomas), primary breast carcinomas, axillary node metastases, and chest wall recurrences. Total PA activity did not differ significantly in the different types of tumors. However, benign tumors contained predominantly t-PA activity. Urokinase-like PA activity was significantly higher in the malignant tumors compared with the benign group. Both t-PA activity and immunoreactive t-PA were significantly lower in chest wall recurrences compared with primary carcinomas. The ratio of t-PA to urokinase activity was significantly decreased between stages 1 and 3 in the primary tumors. Also, immunoreactive t-PA levels were significantly lower in stages 2 and 3 compared with stage 1. No correlation was found between PA (either total or its different forms) and tumor grade, histological type, or the presence or absence of axillary node metastases.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3933824

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.

Authors:  Manfred Schmitt; Karin Mengele; Apostolos Gkazepis; Rudolf Napieralski; Viktor Magdolen; Ute Reuning; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2008-10-15       Impact factor: 2.860

2.  The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells.

Authors:  S M Abidi; E W Howard; J J Dmytryk; J T Pento
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

3.  Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells.

Authors:  J H Axelrod; R Reich; R Miskin
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

4.  Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?

Authors:  J S Gelister; M R Lewin; H E Driver; F Savage; M Mahmoud; P J Gaffney; P B Boulos
Journal:  Gut       Date:  1987-07       Impact factor: 23.059

5.  Aberrant glycosylation associated with enzymes as cancer biomarkers.

Authors:  Danni L Meany; Daniel W Chan
Journal:  Clin Proteomics       Date:  2011-06-03       Impact factor: 3.988

6.  Binding of urokinase to specific receptor sites on human breast cancer membranes.

Authors:  G K Needham; G V Sherbet; J R Farndon; A L Harris
Journal:  Br J Cancer       Date:  1987-01       Impact factor: 7.640

7.  Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer.

Authors:  J Yamashita; M Ogawa; S Yamashita; Y Nakashima; T Saishoji; K Nomura; K Inada; I Kawano
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

8.  Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.

Authors:  D Foucré; C Bouchet; K Hacène; N Pourreau-Schneider; A Gentile; P M Martin; A Desplaces; J Oglobine
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

Review 9.  Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.

Authors:  Niaz Mahmood; Catalin Mihalcioiu; Shafaat A Rabbani
Journal:  Front Oncol       Date:  2018-02-12       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.